US · Healthcare · Diagnostics & Research
EPS came in at 0.01 against a street estimate of -0.19 — a beat of 105.3%.
Analysts rate GeneDx Holdings Corp. a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $90.44.
CONFIDENT GeneDx hit 30,785 tests (+32% YoY) and $114.4M revenue (+11% YoY), returning to profitability early. Core focus: raising collections from 32% genome rate toward 70% industry standard via payer coverage expansion and RCM improvements. Management expects meaningful uplift in Q4 2026, significant gains in 2027. Q2 2026 No geographic segment breakdown provided. Medicaid coverage: 39 states now cover exome or genome; Mississippi added July 1. Analysts pressed timing of collection rate improvements and revenue visibility. Management maintained conservative near-term outlook (Q3 flat collections) while emphasizing 2027 as inflection point. Strong focus on converting coverage gains into actual payment; leadership confident in RCM playbook but disciplined on near-term pacing. 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| Casdin Capital, LLC | 12.43% |
| Corvex Management LP | 10.82% |
| BlackRock Inc | 5.20% |
| William Blair Investment Management, LLC | 4.70% |
| The Goldman Sachs Group Inc | 4.48% |
| ARK Investment Management LLC | 4.44% |
| Citadel Advisors Llc | 2.90% |
| Vanguard Capital Management, LLC | 2.88% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 GENEDX HOLDINGS CORP. (WGS) - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position declined significantly: Cash and cash equivalents fell from $104 | 2026-08-03 |
| Results announced · Q3 2026 GENEDX HOLDINGS CORP – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $114.4 million, up 11% year-over-year • Exome and genome | 2026-08-03 |
| Shareholder vote results · Q2 2026 GENEDX HOLDINGS CORP. - 8-K FILING SUMMARY HEADLINE NUMBERS • 29,675,547 shares of Class A common stock issued and outstanding as of record date (Ap | 2026-06-23 |
| Board / officer change · Q2 2026 GENEDX HOLDINGS CORP. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Mark Gardner appointed as President effective June 15, 2026, reporting to C | 2026-06-16 |
| Quarterly report · Q1 2026 GENEDX HOLDINGS CORP. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $102.3 million (up 17.4% vs. $87.1 million in Q1 2025) • Diag | 2026-05-04 |
| Results announced · Q2 2026 GENEDX HOLDINGS CORP. – SUPPLEMENTAL FINANCIAL INFORMATION SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Full Year 2025 Total | 2026-05-04 |
| Proxy statement · Q4 2025 GENEDX HOLDINGS CORP. – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal No. 1: Elect one Class II director to serve a three-year term | 2026-04-30 |
| Annual report FY2025 GENEDX HOLDINGS CORP. — RETAIL INVESTOR SUMMARY HEADLINE NUMBERS • Fiscal Year: December 31, 2025 • Market Capitalization: Approximately $1.66 billi | 2026-02-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full year 2026 guidance and preliminary 2025 financial results announced GeneDx Holdings Corp. announced preliminary 2025 financial results and 2026 guidance on January 12, 2026. The company disclosed expectations for fourth quarter and full-year 2025 revenue, ex | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GeneDx Holdings Corp. — free to start.
Google PlayApp StoreData updated 2026-09-18.